Characteristics and clinical features of MPN patients who had pulmonary hypertension at the time of diagnosis.
| No. | Age (yr)/gender | Diagnosis | Prognostication | Driver gene mutations | WBC (×109/L) | Hb (g/dL) | Platelet (×109/L) | LDH (×UNL) | Thrombotic eventsa) | Comorbidities | TRV (m/sec) | RVSP (mmHg) | Late thrombotic eventsb) | Follow-up duration (yr) | Alive/dead |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 75/F | ET | R-IPSET-T high | 16.5 | 11.1 | 2,299 | 1.2 | None | None | 3.0 | 41 | No | 4.3 | Alive | |
| 2 | 79/F | ET | R-IPSET-T high | 10.5 | 14.2 | 896 | 1.0 | CI, IHD | HT, DL | 3.7 | 60 | No | 1.2 | Alive | |
| 3 | 80/F | PV | - | 20.7 | 16.3 | 492 | 1.3 | DVT | DM, HT | 3.4 | 51 | No | 1.0 | Alive | |
| 4 | 56/M | PMF | IPSS low | 17.7 | 14.7 | 1,273 | 1.0 | None | CKD | 3.0 | 41 | No | 4.0 | Alive | |
| 5 | 69/M | PMF | IPSS high | 31.1 | 11.0 | 570 | 1.6 | None | CKD | 3.0 | 41 | No | 2.4 | Alive | |
| 6 | 71/F | PMF | IPSS high | 51.2 | 10.2 | 786 | 4.7 | None | DM | 4.1 | 72 | No | 4.1 | Alive | |
| 7 | 79/M | PMF | IPSS intermediate-2 | 9.3 | 9.2 | 579 | 1.5 | None | CKD | 2.9 | 40 | No | 2.4 | Alive | |
| 8 | 82/F | PMF | IPSS intermediate-1 | 19.7 | 12.2 | 2,178 | 1.6 | None | None | 3.1 | 43 | No | 0.6 | Alive |
a)Thrombotic events prior to or at the time of diagnosis. b)Thrombotic events after diagnosis.
Abbreviations: CALR, calreticulin; CI, cerebral infarction; CKD, chronic kidney disease; DL, dyslipidemia; DM, diabetes mellitus; DVT, deep vein thrombosis; ET, essential thrombocythemia; F, female; HT, hypertension; IHD, ischemic heart disease; IPSS, International Prognostic Scoring System; LDH, lactate dehydrogenase; M, male; MPN, myeloproliferative neoplasm; PMF, primary myelofibrosis; PV, polycythemia vera; R-IPSET-T, revised International Prognostic Score for Essential Thrombocythemia-thrombosis; RVSP, right ventricle systolic pressure; TRV, tricuspid regurgitation velocity; UNL, upper normal limit.